Available Online through www.ijptonline.com

Sravani.Kethireddy* et al. /International Journal Of Pharmacy&Technology• PAS• a macrolide: e.g., clarithromycin• linezolid• high-dose INH (if low-level resistance)• interferon-γ• thioridazine• meropenem and clavulanic acid [61]Response to treatment must be obtained by repeated sputum cultures (monthly if possible). Treatmentfor MDR-TB must be given for a minimum of 18 months and cannot be stopped until the patient hasbeen culture-negative for a minimum of nine months. It is not unusual for patients with MDR-TB to beon treatment for two years or more. [55][56]Groups of drugs to treat MDR-TBGroupGroup 1:First-line oral agentsGroup 2:Injectable agentsGroup 3:FluoroquinolonesGroup 4:Oral bacteriostatic secondlineagentsGroup 5:Agents with unclear role intreatment of drug resistant-TBDrugs (abbreviations)• pyrazinamide (Z)• ethambutol (E)• rifabutin (Rfb)• kanamycin (Km)• amikacin (Am)• capreomycin (Cm)• streptomycin (S)• levofloxacin (Lfx)• moxifloxacin (Mfx)• ofloxacin (Ofx)• para-aminosalicylic acid (PAS)• cycloserine (Cs)• terizidone (Trd)• ethionamide (Eto)• protionamide (Pto)• clofazimine (Cfz)• linezolid (Lzd)• amoxicillin/clavulanate (Amx/Clv)• thioacetazone (Thz)• imipenem/cilastatin (Ipm/Cln)• high-dose isoniazid (high-dose H)b• clarithromycin (Clr)IJPT | June 2010 | Vol. 2 | Issue No.2 | 206-244Page 227